MedTrace Logo

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-01-29

No results posted yet for this study

Summary

This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Patients will receive non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells. Patients will receive dosed reduced cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis.

Conditions

  • Graft Vs Host Disease

Interventions

DRUG

Cyclophosphamide

Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.

DRUG

Abatacept

Calcineurin-inhibitor produced by Astellas.

DRUG

Tacrolimus

Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.

Sponsors & Collaborators

Principal Investigators

  • Mohammad Maher Abdul Hay · NYU Langone Health

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-07
Primary Completion
2027-01-30
Completion
2027-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05621759 on ClinicalTrials.gov